🚀
Enjoy a 7-Day Free Trial Thru May 02, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Cellectar Biosciences Inc (NAS:CLRB)
News
Cellectar Biosciences Inc
NAS
:CLRB (USA) Â
$ 3.06
-0.05 (-1.61%)
10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 98.72M
Enterprise V:
$ 97.38M
Volume:
1.04M
Avg Vol (2M):
1.10M
Warning! GuruFocus detected 2 Severe warning signs with CLRB.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
1.04M
Market Cap $:
98.72M
PE Ratio:
At Loss
Avg Vol (2M):
1.10M
Enterprise Value $:
97.38M
PB Ratio:
0
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Cellectar Biosciences Inc (NAS:CLRB) Stock News, Headlines & Updates
Cellectar Biosciences Inc Stock News from GuruFocus
Total 140
1
2
3
4
Mar 28, 2024
Q4 2023 Cellectar Biosciences Inc Earnings Call Transcript
GuruFocus Research
•
11:02pm
Feb 12, 2024
Thinking about buying stock in TOP Financial Group, Macy's, MicroCloud Hologram, Cellectar Biosciences, or New York Community Bancorp?
PRNewswire
•
2:09pm
Thinking about buying stock in Cellectar Biosciences, elf Beauty, Glatfelter, Solidion Technology, or Spectral AI?
PRNewswire
•
2:08pm
Feb 06, 2024
Cellectar Biosciences Inc KOL Call Transcript
GuruFocus Research
•
9:27am
Cellectar Biosciences Inc at EBD Group Biotech Showcase Transcript
GuruFocus Research
•
9:27am
Cellectar Biosciences Inc Top-line Data Call Transcript
GuruFocus Research
•
9:27am
Q3 2023 Cellectar Biosciences Inc Earnings Call Transcript
GuruFocus Research
•
9:27am
Cellectar Biosciences Inc Annual Shareholders Meeting Transcript
GuruFocus Research
•
9:27am
Cellectar Biosciences Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
9:27am
Cellectar Biosciences Inc at ROTH Conference Transcript
GuruFocus Research
•
9:27am
Cellectar Biosciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
GuruFocus Research
•
9:27am
Cellectar Biosciences Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
GuruFocus Research
•
9:27am
Cellectar Biosciences Inc at Next Generation Targeted Cancer Therapies - The Cellectar Story! Transcript
GuruFocus Research
•
9:27am
Jan 25, 2024
Thinking about buying stock in Petros Pharmaceuticals, Xpeng Inc, Nukkleus, Cellectar Biosciences, or bluebird bio?
PRNewswire
•
9:00am
Jan 23, 2024
Thinking about buying stock in QuantaSing, Macy's, Cellectar Biosciences, Schlumberger, or TKO Group?
PRNewswire
•
9:00am
Jan 10, 2024
Thinking about buying stock in Clearmind Medicine, Bitfarms, Safety Shot, Cellectar Biosciences, or Amarin Corporation?
PRNewswire
•
9:00am
Oct 24, 2023
Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
Marketwired
•
7:00am
Oct 17, 2023
Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia
Marketwired
•
7:00am
Oct 02, 2023
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
Marketwired
•
6:00am
Sep 18, 2023
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia
Marketwired
•
8:00am
Sep 11, 2023
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
Marketwired
•
6:00am
Sep 05, 2023
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
Marketwired
•
8:00am
Aug 14, 2023
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
Marketwired
•
8:00am
Jun 28, 2023
Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
Marketwired
•
8:00am
Feb 15, 2023
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
sperokesalga
•
8:00am
Nov 30, 2022
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
Value_Insider
•
8:00am
Nov 21, 2022
Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference
Value_Insider
•
8:00am
Nov 16, 2022
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
Value_Insider
•
8:00am
Nov 03, 2022
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update
Value_Insider
•
8:00am
Oct 21, 2022
Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
Value_Insider
•
8:00am
Aug 05, 2022
Cellectar Reports Financial Results for Second Quarter 2022
PurpleRose
•
8:00am
Apr 12, 2022
Cellectar Biosciences Announces Key Commercial Team Appointments
GuruFocusNews
•
8:00am
Mar 21, 2022
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
GuruFocusNews
•
8:00am
Mar 10, 2022
Cellectar to Participate at Upcoming Banking Conferences
GuruFocusNews
•
4:01pm
Dec 13, 2021
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition
GuruFocusNews
•
8:00am
Dec 08, 2021
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
GuruFocusNews
•
8:00am
Nov 08, 2021
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
Don Li2
•
8:01am
Nov 02, 2021
Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
Don Li2
•
8:00am
Jul 13, 2021
Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
Marketwired
•
8:03am
Jul 12, 2021
Thinking about buying stock in indie Semiconductor, CohBar, Cellectar Biosciences, Lucira Health, or Dare Bioscience?
PRNewswire
•
9:01am
Total 140
1
2
3
4
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news